1. EXECUTIVE SUMMARY
2. MARKET SNAPSHOT
2.1. Market Overview
2.2. Market Definition
2.3. Scope of the Study
2.4. Market Segmentation
3. BUSINESS LANDSCAPE
3.1. Market Drivers
3.2. Market Restraints
3.3. Market Opportunities
3.4. Porter’s Five Forces Analysis
3.5. Industry Value Chain Analysis
3.6. Policies and Regulations
3.7. Strategic Recommendations
4. TECHNOLOGICAL OUTLOOK
5. OPIOID USE DISORDER TREATMENT MARKET BY TREATMENT TYPE
5.1. Introduction
5.2. Medication
5.2.1. Buprenorphine
5.2.2. Methadone
5.2.3. Naltrexone
5.3. Counseling & Behavioral Therapies
6. OPIOID USE DISORDER TREATMENT MARKET BY ROUTE OF ADMINISTRATION
6.1. Introduction
6.2. Oral
6.3. Injectable
7. OPIOID USE DISORDER TREATMENT MARKET BY END-USER
7.1. Introduction
7.2. Rehabilitation Centers
7.3. Specialized Clinics
7.4. Others
8. OPIOID USE DISORDER TREATMENT MARKET BY GEOGRAPHY
8.1. Introduction
8.2. North America
8.2.1. USA
8.2.2. Canada
8.2.3. Mexico
8.3. South America
8.3.1. Brazil
8.3.2. Argentina
8.3.3. Others
8.4. Europe
8.4.1. Germany
8.4.2. France
8.4.3. United Kingdom
8.4.4. Spain
8.4.5. Others
8.5. Middle East and Africa
8.5.1. Saudi Arabia
8.5.2. UAE
8.5.3. Israel
8.5.4. Others
8.6. Asia Pacific
8.6.1. China
8.6.2. India
8.6.3. Japan
8.6.4. South Korea
8.6.5. Indonesia
8.6.6. Thailand
8.6.7. Others
9. COMPETITIVE ENVIRONMENT AND ANALYSIS
9.1. Major Players and Strategy Analysis
9.2. Market Share Analysis
9.3. Mergers, Acquisitions, Agreements, and Collaborations
9.4. Competitive Dashboard
10. COMPANY PROFILES
10.1. Indivior Plc
10.2. Alkermes Plc
10.3. Orexo AB
10.4. Titan Pharmaceuticals Inc.
10.5. Teva Pharmaceutical Industries Ltd.
10.6. Mallinckrodt Pharmaceuticals
10.7. Pfizer Inc.
10.8. Hikma Pharmaceuticals PLC
10.9. Camurus
10.10. Collegium Pharmaceuticals
11. APPENDIX
11.1. Currency
11.2. Assumptions
11.3. Base and Forecast Years Timeline
11.4. Key benefits for the stakeholders
11.5. Research Methodology
11.6. Abbreviations
LIST OF FIGURES
LIST OF TABLES